Switch-Ig™ enables antibody binding to only antigens within the tumor environment and not normal tissues, enabling an efficient and safe form of cancer immunotherapy. This is achieved by our proprietary antibody engineering technology allowing antibodies to bind to target antigens in the presence of extracellular adenosine triphosphate (ATP) which is abundant in tumor microenvironments. Our first Switch Antibody™, STA551, is being tested in clinical studies, and we have multiple Switch Antibody™ projects in the drug discovery stage.
Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation
Cancer Discovery, Published Online First August 25, 2020